Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3661438,maximal,"After receiving intravenous labetalol, elderly patients had a greater maximal mean decrease in systolic blood pressure (BP) (39 +/- 8 vs 25 +/- 13 mm Hg, p less than 0.02); however, maximal decrease in diastolic BP was similar in elderly (18 +/- 10 mm Hg) and young (17 +/- 6 mm Hg) patients.",Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661438/),,18,9317,DB00598,Labetalol
,3661438,Slope,Slope of labetalol concentration vs systolic BP for elderly vs young patients was 0.928 +/- 1.05 vs 0.326 +/- 0.490 ng/ml X mm Hg-1 (difference not significant).,Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661438/),[ng] / [hg·ml·mm],0.928,9318,DB00598,Labetalol
,3661438,Slope,Slope of labetalol concentration vs systolic BP for elderly vs young patients was 0.928 +/- 1.05 vs 0.326 +/- 0.490 ng/ml X mm Hg-1 (difference not significant).,Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661438/),[ng] / [hg·ml·mm],0.326,9319,DB00598,Labetalol
,3661438,concentration,"The slope of labetalol concentration vs heart rate for elderly vs young patients was 0.176 +/- 0.063 vs 0.406 +/- 0.303 ng/ml X beats/min-1 (p less than 0.05), with 2 elderly patients showing no decrease in heart rate.",Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661438/),[ng] / [beats·min·ml],0.176,9320,DB00598,Labetalol
,3661438,concentration,"The slope of labetalol concentration vs heart rate for elderly vs young patients was 0.176 +/- 0.063 vs 0.406 +/- 0.303 ng/ml X beats/min-1 (p less than 0.05), with 2 elderly patients showing no decrease in heart rate.",Comparison in young and elderly patients of pharmacodynamics and disposition of labetalol in systemic hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3661438/),[ng] / [beats·min·ml],0.406,9321,DB00598,Labetalol
,1412606,absolute bioavailability,"Similarly, the absolute bioavailability of an oral dose of 200 mg of labetalol was 0.33 in ESRD patients and was not significantly different from that of normal volunteers (0.26).",Bioavailability of labetalol in patients with end-stage renal disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412606/),,0.33,11547,DB00598,Labetalol
,1412606,absolute bioavailability,"Similarly, the absolute bioavailability of an oral dose of 200 mg of labetalol was 0.33 in ESRD patients and was not significantly different from that of normal volunteers (0.26).",Bioavailability of labetalol in patients with end-stage renal disease. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1412606/),,0.26,11548,DB00598,Labetalol
,19640235,heart rate,"Two hours after admission, vital signs were blood pressure 259/107 mmHg and heart rate 140 beats/min.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),[beats] / [min],140,34374,DB00598,Labetalol
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,"1,530",34375,DB00598,Labetalol
,19640235,blood levels,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),,865,34376,DB00598,Labetalol
,19640235,half-life,"The yohimbine blood levels at 3, 6, 14, and 22 h after ingestion were 5,240; 2,250; 1,530; and 865 ng/mL, respectively, with a mean half-life of 2 h.",Acute neurotoxicity after yohimbine ingestion by a body builder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19640235/),h,2,34377,DB00598,Labetalol
,9498675,flow-rate,"A 5 mM acetate buffer (pH 4.5)-acetonitrile (70:30, v/v) mixture was employed as the mobile phase, pumped at a flow-rate of 1 ml/min.",Quantitative determination of the beta-blocker labetalol in pharmaceuticals and human urine by high-performance liquid chromatography with amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498675/),[ml] / [min],1,37224,DB00598,Labetalol
higher,9498675,recoveries,"Sample preparation was carried out using a simple solid-phase extraction (SPE) procedure, and recoveries higher than 85% were achieved.",Quantitative determination of the beta-blocker labetalol in pharmaceuticals and human urine by high-performance liquid chromatography with amperometric detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498675/),%,85,37225,DB00598,Labetalol
,8240457,systemic plasma clearance,From the obtained data the systemic plasma clearance was calculated to be 1708 ml/min.,"Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),[ml] / [min],1708,43267,DB00598,Labetalol
,8240457,oral bioavailability,The oral bioavailability was calculated to be 16%.,"Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,16,43268,DB00598,Labetalol
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,0.5,43269,DB00598,Labetalol
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,23,43270,DB00598,Labetalol
,8240457,fractions of,"In volunteers the fractions of the dose excreted renally were 0.5% for parent drug, 23% for the glucuronide(s) and 8% for the sulfate.","Pharmacokinetics of dilevalol and its conjugates in man. Assay method for plasma, blood, urine and bile samples and preliminary pharmacokinetic studies. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8240457/),%,8,43271,DB00598,Labetalol
,22282956,flow rate,"The chromatographic separation was achieved with a reverse phase column (4.6 x 50 mm, 5 microm) and the mobile phase consisted of cyanomethane and 5 mM ammonium formate buffer pH 4.5 (70:30 v/v) as eluent, at a flow rate of 0.6 mL/min.","Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282956/),[ml] / [min],0.6,59451,DB00598,Labetalol
,22282956,retention times,The retention times of flupirtine and labetalol were found to be 2.16 and 1.66 min respectively.,"Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282956/),min,2.16,59452,DB00598,Labetalol
,22282956,retention times,The retention times of flupirtine and labetalol were found to be 2.16 and 1.66 min respectively.,"Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282956/),min,1.66,59453,DB00598,Labetalol
above,22282956,extraction recovery,Mean extraction recovery was found to be above 86.5%.,"Bioanalytical method development, validation and quantification of flupirtine maleate in rat plasma by liquid chromatography-tandem mass spectrometry. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22282956/),%,86.5,59454,DB00598,Labetalol
,1501116,total body clearance,"Labetalol shows a triexponential decline in the mother with a total body clearance of 30.8 +/- 3.83 ml/min/kg, an apparent steady-state volume of distribution (nonparametric) of 3.02 +/- 0.18 liters/kg and terminal elimination half-life of 2.79 +/- 0.66 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),[ml] / [kg·min],30.8,67566,DB00598,Labetalol
,1501116,apparent steady-state volume of distribution,"Labetalol shows a triexponential decline in the mother with a total body clearance of 30.8 +/- 3.83 ml/min/kg, an apparent steady-state volume of distribution (nonparametric) of 3.02 +/- 0.18 liters/kg and terminal elimination half-life of 2.79 +/- 0.66 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),[l] / [kg],3.02,67567,DB00598,Labetalol
,1501116,terminal elimination half-life,"Labetalol shows a triexponential decline in the mother with a total body clearance of 30.8 +/- 3.83 ml/min/kg, an apparent steady-state volume of distribution (nonparametric) of 3.02 +/- 0.18 liters/kg and terminal elimination half-life of 2.79 +/- 0.66 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),h,2.79,67568,DB00598,Labetalol
,1501116,peak fetal plasma concentration,"The peak fetal plasma concentration was 33.7 +/- 5.8 ng/ml, the fetal exposure to labetalol as calculated by the fetal to maternal area under the curve ratio was 14.37 +/- 1.54% and the apparent fetal elimination half-life was 3.71 +/- 0.5 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),[ng] / [ml],33.7,67569,DB00598,Labetalol
,1501116,area under the curve ratio,"The peak fetal plasma concentration was 33.7 +/- 5.8 ng/ml, the fetal exposure to labetalol as calculated by the fetal to maternal area under the curve ratio was 14.37 +/- 1.54% and the apparent fetal elimination half-life was 3.71 +/- 0.5 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),%,14.37,67570,DB00598,Labetalol
,1501116,apparent fetal elimination half-life,"The peak fetal plasma concentration was 33.7 +/- 5.8 ng/ml, the fetal exposure to labetalol as calculated by the fetal to maternal area under the curve ratio was 14.37 +/- 1.54% and the apparent fetal elimination half-life was 3.71 +/- 0.5 hr.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),h,3.71,67571,DB00598,Labetalol
,1501116,peak concentrations,"Lactic acid accumulates in the fetal blood and amniotic fluid with peak concentrations (6.0 +/- 0.31 and 5.5 +/- 0.26 mM, respectively) showing a more than 300% increase over control values.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),mM,6.0,67572,DB00598,Labetalol
,1501116,peak concentrations,"Lactic acid accumulates in the fetal blood and amniotic fluid with peak concentrations (6.0 +/- 0.31 and 5.5 +/- 0.26 mM, respectively) showing a more than 300% increase over control values.",Pharmacokinetics and pharmacodynamics of labetalol in the pregnant sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1501116/),mM,5.5,67573,DB00598,Labetalol
,6356898,elimination half life,"At steady state, the absorption, distribution, and elimination kinetics were similar for both dosage regimens with elimination half life of 7.65 and 7.92 hours for the 200 mg three times a day and 300 mg twice a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),h,7.65,69752,DB00598,Labetalol
,6356898,elimination half life,"At steady state, the absorption, distribution, and elimination kinetics were similar for both dosage regimens with elimination half life of 7.65 and 7.92 hours for the 200 mg three times a day and 300 mg twice a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),h,7.92,69753,DB00598,Labetalol
,6356898,steady-state plasma drug concentrations,"During the multiple dosing period average steady-state plasma drug concentrations were 0.149 mg/ml and 0.145 mg/ml for the 300 mg twice a day and 200 mg three times a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),[mg] / [ml],0.149,69754,DB00598,Labetalol
,6356898,steady-state plasma drug concentrations,"During the multiple dosing period average steady-state plasma drug concentrations were 0.149 mg/ml and 0.145 mg/ml for the 300 mg twice a day and 200 mg three times a day regimens, respectively.",Study of single and multiple dose pharmacokinetic/pharmacodynamic modeling of the antihypertensive effects of labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6356898/),[mg] / [ml],0.145,69755,DB00598,Labetalol
,26635159,elimination half-life,The mean elimination half-life was 3.25 hours.,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26635159/),h,3.25,82457,DB00598,Labetalol
,26635159,Systemic availability,Systemic availability varied from 11-86% (mean 33%).,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26635159/),%,33,82458,DB00598,Labetalol
,2454374,half-life,Calculation of the half-life of carvedilol gave values of 2.2 to 9 h.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),h,2.2 to 9,83799,DB00598,Labetalol
,2454374,volume of distribution,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [kg],1.54,83800,DB00598,Labetalol
,2454374,total body clearance,The volume of distribution was found to be 1.54 l/kg and the total body clearance was 0.521 l/h/kg.,Mechanism of the vasodilatory effect of carvedilol in normal volunteers: a comparison with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454374/),[l] / [h·kg],0.521,83801,DB00598,Labetalol
,1457468,absolute recovery,The absolute recovery of 3-APB following extraction from urine and bile was found to be 102.9 +/- 4.9% and 98.3 +/- 1.45% (mean +/- SEM) respectively.,Identification and quantitation of an oxidative metabolite of labetalol in sheep: pharmacokinetic and metabolic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457468/),%,102.9,86648,DB00598,Labetalol
,1457468,absolute recovery,The absolute recovery of 3-APB following extraction from urine and bile was found to be 102.9 +/- 4.9% and 98.3 +/- 1.45% (mean +/- SEM) respectively.,Identification and quantitation of an oxidative metabolite of labetalol in sheep: pharmacokinetic and metabolic implications. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457468/),%,98.3,86649,DB00598,Labetalol
,1457468,cumulative amount,The cumulative amount of 3-APB excreted in urine over 24 h was found to be 71.55 micrograms in one animal following a 100 mg dose of labetalol.,Identification and quantitation of an oxidative metabolite of labetalol in sheep: pharmacokinetic and metabolic implications. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1457468/),μg,71.55,86650,DB00598,Labetalol
,6961762,elimination half-life,The elimination half-life was 1.6 to 8.5 h for the first 8 h.,Single-dose pharmacokinetics of labetalol in healthy young men. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961762/),h,1.6 to 8.5,89168,DB00598,Labetalol
,6961762,oral bioavailability,The oral bioavailability ranged from 4 to 23%.,Single-dose pharmacokinetics of labetalol in healthy young men. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6961762/),%,4 to 23,89169,DB00598,Labetalol
,3676053,steady state plasma concentration (Css),The mean measured steady state plasma concentration (Css) (264 +/- 46 ng ml-1) was higher than predicted (170 ng ml-1) because the clearance (13.1 +/- 2.4 ml kg-1 min-1) was lower than that used to calculate the infusion rate.,Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3676053/),[ng] / [ml],264,90995,DB00598,Labetalol
,3676053,steady state plasma concentration (Css),The mean measured steady state plasma concentration (Css) (264 +/- 46 ng ml-1) was higher than predicted (170 ng ml-1) because the clearance (13.1 +/- 2.4 ml kg-1 min-1) was lower than that used to calculate the infusion rate.,Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3676053/),[ng] / [ml],170,90996,DB00598,Labetalol
,3676053,clearance,The mean measured steady state plasma concentration (Css) (264 +/- 46 ng ml-1) was higher than predicted (170 ng ml-1) because the clearance (13.1 +/- 2.4 ml kg-1 min-1) was lower than that used to calculate the infusion rate.,Continuous i.v. infusion of labetalol for postoperative hypertension. Haemodynamic effects and plasma kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3676053/),[ml] / [kg·min],13.1,90997,DB00598,Labetalol
,23090703,peak concentration,"Subjects with the CYP2C19 2/ 2 genotype had a higher peak concentration (255.5 ± 80.1 vs. 156.0 ± 66.3 ng/mL; P < 0.05) and area under the concentration-time curve (AUC0-∞; 1,473.7 ± 493.6 vs. 502.8 ± 176.1 ng[Symbol: see text]h/mL; P < 0.001) than subjects with 60 or 28, and UGT2B7 2 did not result in a significant effect.",CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090703/),[ng] / [ml],255.5,105706,DB00598,Labetalol
,23090703,peak concentration,"Subjects with the CYP2C19 2/ 2 genotype had a higher peak concentration (255.5 ± 80.1 vs. 156.0 ± 66.3 ng/mL; P < 0.05) and area under the concentration-time curve (AUC0-∞; 1,473.7 ± 493.6 vs. 502.8 ± 176.1 ng[Symbol: see text]h/mL; P < 0.001) than subjects with 60 or 28, and UGT2B7 2 did not result in a significant effect.",CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090703/),[ng] / [ml],156.0,105707,DB00598,Labetalol
,23090703,area under the concentration-time curve (AUC0-∞,"Subjects with the CYP2C19 2/ 2 genotype had a higher peak concentration (255.5 ± 80.1 vs. 156.0 ± 66.3 ng/mL; P < 0.05) and area under the concentration-time curve (AUC0-∞; 1,473.7 ± 493.6 vs. 502.8 ± 176.1 ng[Symbol: see text]h/mL; P < 0.001) than subjects with 60 or 28, and UGT2B7 2 did not result in a significant effect.",CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090703/),ng,"1,473.7",105708,DB00598,Labetalol
,23090703,area under the concentration-time curve (AUC0-∞,"Subjects with the CYP2C19 2/ 2 genotype had a higher peak concentration (255.5 ± 80.1 vs. 156.0 ± 66.3 ng/mL; P < 0.05) and area under the concentration-time curve (AUC0-∞; 1,473.7 ± 493.6 vs. 502.8 ± 176.1 ng[Symbol: see text]h/mL; P < 0.001) than subjects with 60 or 28, and UGT2B7 2 did not result in a significant effect.",CYP2C19 genotype has a major influence on labetalol pharmacokinetics in healthy male Chinese subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23090703/),ng,502.8,105709,DB00598,Labetalol
,3700682,half-lives of the absorption,"The half-lives of the absorption, distribution, and elimination phases are 0.6, 1.3, and 8.3 hours, respectively.",Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700682/),h,0.6,111158,DB00598,Labetalol
,3700682,half-lives of the absorption,"The half-lives of the absorption, distribution, and elimination phases are 0.6, 1.3, and 8.3 hours, respectively.",Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700682/),h,1.3,111159,DB00598,Labetalol
,3700682,half-lives of the absorption,"The half-lives of the absorption, distribution, and elimination phases are 0.6, 1.3, and 8.3 hours, respectively.",Rising multiple-dose pharmacokinetics of labetalol in hypertensive patients. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3700682/),h,8.3,111160,DB00598,Labetalol
,526397,elimination half-life,The mean elimination half-life was 3.25 hours.,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/526397/),h,3.25,119188,DB00598,Labetalol
,526397,Systemic availability,Systemic availability varied from 11-86% (mean 33%).,Pharmacokinetics and pharmacodynamic studies of labetalol in hypertensive subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/526397/),%,33,119189,DB00598,Labetalol
,1954075,elimination half-life,"2. There were no significant age-related changes in pharmacokinetics for either acute or chronic treatment with dilevalol, although there were significant changes in elimination half-life from 7.8 to 11.7 h (P less than 0.05) and in AUC from 261 to 352 ng ml-1 h (P less than 0.005) following translation from acute to chronic dosing.","The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954075/),h,7,131109,DB00598,Labetalol
,1954075,elimination half-life,"2. There were no significant age-related changes in pharmacokinetics for either acute or chronic treatment with dilevalol, although there were significant changes in elimination half-life from 7.8 to 11.7 h (P less than 0.05) and in AUC from 261 to 352 ng ml-1 h (P less than 0.005) following translation from acute to chronic dosing.","The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954075/),h,11,131110,DB00598,Labetalol
,1954075,AUC,"2. There were no significant age-related changes in pharmacokinetics for either acute or chronic treatment with dilevalol, although there were significant changes in elimination half-life from 7.8 to 11.7 h (P less than 0.05) and in AUC from 261 to 352 ng ml-1 h (P less than 0.005) following translation from acute to chronic dosing.","The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954075/),[h·ng] / [ml],261,131111,DB00598,Labetalol
,1954075,AUC,"2. There were no significant age-related changes in pharmacokinetics for either acute or chronic treatment with dilevalol, although there were significant changes in elimination half-life from 7.8 to 11.7 h (P less than 0.05) and in AUC from 261 to 352 ng ml-1 h (P less than 0.005) following translation from acute to chronic dosing.","The effects of age on the pharmacokinetics, antihypertensive efficacy and general tolerability of dilevalol. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1954075/),[h·ng] / [ml],352,131112,DB00598,Labetalol
,3392232,V beta/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [kg],18,133237,DB00598,Labetalol
,3392232,Vdss/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [kg],161,133238,DB00598,Labetalol
,3392232,Vdss/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [kg],7.1,133239,DB00598,Labetalol
,3392232,Vdss/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [h·kg],1.3,133240,DB00598,Labetalol
,3392232,Vdss/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),h,6.9,133241,DB00598,Labetalol
,3392232,TBC/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [kg],7.1,133242,DB00598,Labetalol
,3392232,TBC/F,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),h,6.9,133243,DB00598,Labetalol
,3392232,t1/2 beta,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[l] / [kg],7.1,133244,DB00598,Labetalol
,3392232,t1/2 beta,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),h,6.9,133245,DB00598,Labetalol
,3392232,AUC tau 0,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),h,11.0,133246,DB00598,Labetalol
,3392232,AUC tau 0,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[h·μg] / [l],154,133247,DB00598,Labetalol
,3392232,AUC tau 0,"The mean V beta/F, Vdss/F, TBC/F, t1/2 beta, and AUC tau 0 for each subject ranged between 18.1 and 161.9 L/kg, 7.1 and 53.9 L/kg, 1.3 and 5.72 L/hr/kg, 6.9 and 11.0 hours, and 154 and 520 micrograms.hr/L, respectively, indicating large interindividual variability.",Interindividual and intraindividual variability in labetalol pharmacokinetics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3392232/),[h·μg] / [l],520,133248,DB00598,Labetalol
,8363681,time to control,The mean time to control was 67.5 minutes for labetalol and 60.0 minutes for nifedipine (P > .2).,Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363681/),min,67.5,134042,DB00598,Labetalol
,8363681,time to control,The mean time to control was 67.5 minutes for labetalol and 60.0 minutes for nifedipine (P > .2).,Oral labetalol versus oral nifedipine in hypertensive urgencies in the ED. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8363681/),min,60.0,134043,DB00598,Labetalol
,1687880,low detection limit,The low detection limit of this method in the patient was 3 ng/mL.,Determination of vecuronium in blood by HPLC with UV and electrochemical detection: a pilot study in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1687880/),[ng] / [ml],3,142308,DB00598,Labetalol
,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,10,143406,DB00598,Labetalol
over,6370541,bioavailability,The bioavailability varies from 10% to over 80% in different subjects.,Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,80,143407,DB00598,Labetalol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,30,143408,DB00598,Labetalol
,6370541,bioavailability,"Average bioavailability has been reported to correlate with age, with values of approximately 30% in the 30- to 40-year age group and approximately 65% at 80 years.",Clinical pharmacokinetics of labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),%,65,143409,DB00598,Labetalol
,6370541,apparent volume of distribution at equilibrium,"The apparent volume of distribution at equilibrium varies from approximately 200 to over 800L, suggesting that concentration of labetalol occurs in extravascular sites.",Clinical pharmacokinetics of labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),l,200 to over 800,143410,DB00598,Labetalol
,6370541,half-life,The half-life of labetalol in plasma is 3 to 3.5 hours.,Clinical pharmacokinetics of labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6370541/),h,3 to 3.5,143411,DB00598,Labetalol
,6145441,"terminal elimination half-life (t 1/2,Z)","For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,15.6,143493,DB00598,Labetalol
,6145441,peak level,"For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ng] / [ml],450,143494,DB00598,Labetalol
,6145441,time to peak,"For oral medroxalol the clinical pharmacokinetic parameters were a terminal elimination half-life (t 1/2,Z) of 15.6 h, a peak level of 450 ng/ml and a time to peak of 2-3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,2-3,143495,DB00598,Labetalol
,6145441,bioavailability,"Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,64,143496,DB00598,Labetalol
,6145441,plasma clearance,"Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],948,143497,DB00598,Labetalol
,6145441,"t 1/2,Z","Following intravenous medroxalol the bioavailability was calculated as 64%, the plasma clearance was 948 ml/min and the t 1/2,Z was 7.3 h.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,7.3,143498,DB00598,Labetalol
,6145441,time to peak,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,2.3,143499,DB00598,Labetalol
,6145441,time to peak,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,1.1,143500,DB00598,Labetalol
,6145441,oral t 1/2,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,15.6,143501,DB00598,Labetalol
,6145441,oral t 1/2,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),h,5.5,143502,DB00598,Labetalol
,6145441,clearance,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],948,143503,DB00598,Labetalol
,6145441,clearance,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),[ml] / [min],1560,143504,DB00598,Labetalol
,6145441,bioavailability,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,64,143505,DB00598,Labetalol
,6145441,bioavailability,"The significant differences between medroxalol and labetalol were in time to peak, respectively 2.3 and 1.1 h; oral t 1/2,Z, 15.6 and 5.5 h; clearance 948 and 1560 ml/min; and bioavailability, 64 and 20%.",Comparison of the clinical pharmacokinetics and concentration-effect relationships for medroxalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6145441/),%,20,143506,DB00598,Labetalol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],2.16,151014,DB00598,Labetalol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],2.35,151015,DB00598,Labetalol
,6849783,Clearance,"Clearance values (1 min-1) were: pregnant, 2.16 (range 1.54-3.14); postpartum 2.35 (1.56-3.85); controls 1.96 (0.98-2.61).",Labetalol disposition and concentration-effect relationships during pregnancy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6849783/),[1] / [min],1.96,151016,DB00598,Labetalol
,2598569,systemic clearance,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),[ml] / [kg·min],29.8,151422,DB00598,Labetalol
,2598569,volume of distribution,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),[l] / [kg],16.6,151423,DB00598,Labetalol
,2598569,terminal half-life,"The three-compartment model analysis showed that systemic clearance (29.8 +/- 5.7 ml/min/kg), volume of distribution (16.6 +/- 4.1 L/kg), and terminal half-life (11.7 +/- 2.7 hours) were not altered by cimetidine.",Pharmacokinetics and pharmacodynamics of dilevalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2598569/),h,11.7,151424,DB00598,Labetalol
,8245166,limit of detection,The limit of detection of the individual isomers was 0.15 ng (0.6 ng of injected racemic labetalol).,Sensitive high-performance liquid chromatographic method for direct separation of labetalol stereoisomers in biological fluids using an alpha 1-acid glycoprotein stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245166/),ng,0.15,159468,DB00598,Labetalol
,8245166,limit of detection,The limit of detection of the individual isomers was 0.15 ng (0.6 ng of injected racemic labetalol).,Sensitive high-performance liquid chromatographic method for direct separation of labetalol stereoisomers in biological fluids using an alpha 1-acid glycoprotein stationary phase. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8245166/),ng,0.6,159469,DB00598,Labetalol
,8227470,elimination half-lives,"The elimination half-lives ranged from 4.3 to 6.9 hours, and the apparent oral clearance from 31.9 to 73.3 mL/min/kg.",Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227470/),h,4.3 to 6.9,163526,DB00598,Labetalol
,8227470,apparent oral clearance,"The elimination half-lives ranged from 4.3 to 6.9 hours, and the apparent oral clearance from 31.9 to 73.3 mL/min/kg.",Labetalol in hypertension during the third trimester of pregnancy: its antihypertensive effect and pharmacokinetic-dynamic analysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8227470/),[ml] / [kg·min],31.9 to 73.3,163527,DB00598,Labetalol
,8097698,net output,The net output of lactate from the hindquarter over 12 hr following drug administration was calculated to be 6.25 +/- 1.35 g (0.07 +/- 0.015 mol).,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),g,6.25,166654,DB00598,Labetalol
,8097698,net output,The net output of lactate from the hindquarter over 12 hr following drug administration was calculated to be 6.25 +/- 1.35 g (0.07 +/- 0.015 mol).,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),mol,0.07,166655,DB00598,Labetalol
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,1.61,166656,DB00598,Labetalol
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,11.46,166657,DB00598,Labetalol
,8097698,cumulative urinary excretion,"The cumulative urinary excretion of labetalol as unchanged drug, glucuronide and sulfate was found to be 1.61 +/- 0.3, 11.46 +/- 2.83, and 1.47 +/- 0.74% of the dose, respectively.","Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),%,1.47,166658,DB00598,Labetalol
,8097698,apparent elimination half-life,Pharmacokinetic analysis shows the apparent elimination half-life of the metabolite to be 13.5 +/- 3.8 min.,"Disposition, metabolism, and pharmacodynamics of labetalol in adult sheep. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8097698/),min,13.5,166659,DB00598,Labetalol
,1884570,bioavailability,"Both drugs are rapidly and completely absorbed in 60 to 90 min and subject to extensive first-pass hepatic metabolism; the average bioavailability after oral administration is around 20 to 35%, and there is wide interindividual variability in plasma drug concentrations and dosage requirements.",Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884570/),%,20 to 35,167383,DB00598,Labetalol
,1884570,volume of distribution,"The volume of distribution of dilevalol (17 to 25 L/kg) is higher than that reported for labetalol (3 to 16 L/kg), although both drugs are concentrated in the extravascular compartment.",Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884570/),[l] / [kg],17 to 25,167384,DB00598,Labetalol
,1884570,volume of distribution,"The volume of distribution of dilevalol (17 to 25 L/kg) is higher than that reported for labetalol (3 to 16 L/kg), although both drugs are concentrated in the extravascular compartment.",Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884570/),[l] / [kg],3 to 16,167385,DB00598,Labetalol
,1884570,elimination half-life,"Correspondingly, the elimination half-life of dilevalol at steady-state is around 15h compared with 8h for labetalol.",Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884570/),h,15,167386,DB00598,Labetalol
,1884570,elimination half-life,"Correspondingly, the elimination half-life of dilevalol at steady-state is around 15h compared with 8h for labetalol.",Clinical pharmacokinetics and kinetic-dynamic relationships of dilevalol and labetalol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1884570/),h,8,167387,DB00598,Labetalol
more,19006203,recovery,"The four labetalol stereoisomers were analyzed by LC-MS/MS on a Chirobiotic V column using a mobile phase consisting of methanol, acetic acid, and diethylamine, with a recovery of more than 90% for all four.",Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19006203/),%,90,172823,DB00598,Labetalol
,19006203,"AUC(R,R)/AUC(S,S) ratio","The stereoselectivity observed after oral administration is due to the hepatic metabolism and the first pass effect, with an AUC(R,R)/AUC(S,S) ratio of 0.5.",Stereoselective analysis of labetalol in human plasma by LC-MS/MS: application to pharmacokinetics. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19006203/),,0.5,172824,DB00598,Labetalol
,2309815,peak serum concentrations,Labetalol exhibited rapid absorption; peak serum concentrations of 881 +/- 219 ng/ml occurred at 20 minutes after labetalol ingestion.,Labetalol pharmacokinetics in pregnancy-induced hypertension. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2309815/),[ng] / [ml],881,179370,DB00598,Labetalol
,2309815,terminal elimination half-life,"The terminal elimination half-life (mean, 1.7 +/- 0.27 hours) was found to be shorter than that reported for normotensive volunteers or nonpregnant hypertensive patients (mean, 6 to 8 hours).",Labetalol pharmacokinetics in pregnancy-induced hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2309815/),h,1.7,179371,DB00598,Labetalol
,2309815,terminal elimination half-life,"The terminal elimination half-life (mean, 1.7 +/- 0.27 hours) was found to be shorter than that reported for normotensive volunteers or nonpregnant hypertensive patients (mean, 6 to 8 hours).",Labetalol pharmacokinetics in pregnancy-induced hypertension. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2309815/),h,6 to 8,179372,DB00598,Labetalol
,2309815,apparent oral elimination clearance,A mean apparent oral elimination clearance of 21.8 ml/min/kg compared favorably with that seen in other pregnant and nonpregnant populations.,Labetalol pharmacokinetics in pregnancy-induced hypertension. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2309815/),[ml] / [kg·min],21.8,179373,DB00598,Labetalol
,2309815,time to peak serum concentration,Food delayed the time to peak serum concentration to approximately 60 minutes.,Labetalol pharmacokinetics in pregnancy-induced hypertension. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2309815/),min,60,179374,DB00598,Labetalol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,72.4,187766,DB00598,Labetalol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,73.0,187767,DB00598,Labetalol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,56.7,187768,DB00598,Labetalol
,31862675,recovery (%),"Mean recovery (%) values in aqueous humor and plasma were 72.4% and 73.0% for nebivolol and 56.7% and 54.4% for labetalol, respectively.",Development and validation of a bio-analytical method for simultaneous quantification of nebivolol and labetalol in aqueous humor and plasma using LC-MS/MS and its application to ocular pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31862675/),%,54.4,187769,DB00598,Labetalol
,7093102,steady-state levels,2 Mean steady-state levels varied from 36 to 183 ng/ml on a chronic dose of 200 mg twice daily.,Labetalol steady-state pharmacokinetics in hypertensive patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093102/),[ng] / [ml],36 to 183,190307,DB00598,Labetalol
down,7329771,detection limit,The method is highly selective for the compounds of interest with a detection limit down to 1 ng/ml.,HPLC-analysis and preliminary pharmacokinetic parameter estimations of chloroquine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7329771/),[ng] / [ml],1,190831,DB00598,Labetalol
,8913406,f,"The fetal-maternal plasma accumulation ratio of 1.6:1 indicates that at this gestational age after 26 days of therapy, the placental transfer of phenoxybenzamine occurs and is accompanied by accumulation in the fetal blood.",Phenoxybenzamine placental transfer during the third trimester. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8913406/),:,1.6,197970,DB00598,Labetalol
,8913406,plasma accumulation ratio,"The fetal-maternal plasma accumulation ratio of 1.6:1 indicates that at this gestational age after 26 days of therapy, the placental transfer of phenoxybenzamine occurs and is accompanied by accumulation in the fetal blood.",Phenoxybenzamine placental transfer during the third trimester. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8913406/),:,1.6,197971,DB00598,Labetalol
,10853616,area under the concentration-time curve [AUC]/dose x 1000,"Labetalol concentrations were 80% higher in women (area under the concentration-time curve [AUC]/dose x 1000: 6.79 +/- 2.11 in women vs 3.82 +/- 1.37 hr/L in men, p<0.05), yet both genders had a similar antihypertensive response by 24-hour ABPM.",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],6.79,198781,DB00598,Labetalol
,10853616,area under the concentration-time curve [AUC]/dose x 1000,"Labetalol concentrations were 80% higher in women (area under the concentration-time curve [AUC]/dose x 1000: 6.79 +/- 2.11 in women vs 3.82 +/- 1.37 hr/L in men, p<0.05), yet both genders had a similar antihypertensive response by 24-hour ABPM.",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],3.82,198782,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],7.55,198783,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],4.83,198784,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],8.23,198785,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],4.65,198786,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],6.99,198787,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],4.25,198788,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],3.91,198789,DB00598,Labetalol
,10853616,Dose-corrected AUC (AUC/dose x 1000),"Dose-corrected AUC (AUC/dose x 1000) for labetalol's stereoisomers in women and men, respectively, were S,R-labetalol 7.55 +/- 1.47 and 4.83 +/- 1.54 hr/L (p<0.05), S,S-labetalol 8.23 +/- 2.93 and 4.65 +/- 1.78 hr/L (p<0.05), R,S-labetalol 6.99 +/- 3.30 and 4.25 +/- 2.35 hr/L (p=0.11), and R,R-labetalol 3.91 +/- 2.57 and 3.55 +/- 3.08 hr/L (NS).",Gender differences in labetalol kinetics: importance of determining stereoisomer kinetics for racemic drugs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10853616/),[h] / [l],3.55,198790,DB00598,Labetalol
,2225711,Oral clearance,"Oral clearance of labetalol decreased with cimetidine administration (58.7 +/- 23.3 to 32.9 +/- 13.2 ml/min/kg; p less than 0.05), thereby causing a 79% increase in area under the curve.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],58.7,202610,DB00598,Labetalol
,2225711,Oral clearance,"Oral clearance of labetalol decreased with cimetidine administration (58.7 +/- 23.3 to 32.9 +/- 13.2 ml/min/kg; p less than 0.05), thereby causing a 79% increase in area under the curve.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],32.9,202611,DB00598,Labetalol
,2225711,systemic clearance,"Labetalol systemic clearance also decreased (23.2 +/- 5.3 to 17.7 +/- 3.7 ml/min/kg; p less than 0.05), but the volume of distribution was unchanged.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],23.2,202612,DB00598,Labetalol
,2225711,systemic clearance,"Labetalol systemic clearance also decreased (23.2 +/- 5.3 to 17.7 +/- 3.7 ml/min/kg; p less than 0.05), but the volume of distribution was unchanged.",Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2225711/),[ml] / [kg·min],17.7,202613,DB00598,Labetalol
,2616255,half-life,"The half-life of labetalol in the plasma of the infant was found to be approximately 24 h, i.e. substantially longer than in normal adults.",Half-life of maternal labetalol in a premature infant. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2616255/),h,24,212533,DB00598,Labetalol
,7203731,T 1/2,"After intravenous injections (n = 4) of 1.5 mg/kg, the drug was rapidly distributed (mean T 1/2 = 4.9 min) and quite rapidly eliminated (mean T 1/2 = 4.9 hrs).",Pharmacokinetics of labetalol in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),min,4.9,215137,DB00598,Labetalol
,7203731,T 1/2,"After intravenous injections (n = 4) of 1.5 mg/kg, the drug was rapidly distributed (mean T 1/2 = 4.9 min) and quite rapidly eliminated (mean T 1/2 = 4.9 hrs).",Pharmacokinetics of labetalol in healthy volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),h,4.9,215138,DB00598,Labetalol
,7203731,total plasma clearance,The mean total plasma clearance value was 24.80 ml/min/kg.,Pharmacokinetics of labetalol in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[ml] / [kg·min],24.80,215139,DB00598,Labetalol
,7203731,Vdc,The values for Vdc (mean 1.1 l/kg) and Vdss (mean 9.41 l/kg) indicate extensive extravascular distribution of labetalol.,Pharmacokinetics of labetalol in healthy volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[l] / [kg],1.1,215140,DB00598,Labetalol
,7203731,Vdss,The values for Vdc (mean 1.1 l/kg) and Vdss (mean 9.41 l/kg) indicate extensive extravascular distribution of labetalol.,Pharmacokinetics of labetalol in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),[l] / [kg],9.41,215141,DB00598,Labetalol
,7203731,systemic availability,The systemic availability was about 18%.,Pharmacokinetics of labetalol in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7203731/),%,18,215142,DB00598,Labetalol
,2729127,absolute oral bioavailability,"Studies of dilevalol's pharmacokinetics in normotensive and hypertensive volunteers have demonstrated that (1) it is rapidly and well absorbed; (2) because of extensive first-pass metabolism its absolute oral bioavailability is about 12%; (3) its mean elimination half-life is 8 to 12 hours after administration of single oral or intravenous doses to normal volunteers, a value consistent with once-daily dosing; and (4) food does not appear to alter its bioavailability or pharmacokinetics.",Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729127/),%,12,216209,DB00598,Labetalol
,2729127,elimination half-life,"Studies of dilevalol's pharmacokinetics in normotensive and hypertensive volunteers have demonstrated that (1) it is rapidly and well absorbed; (2) because of extensive first-pass metabolism its absolute oral bioavailability is about 12%; (3) its mean elimination half-life is 8 to 12 hours after administration of single oral or intravenous doses to normal volunteers, a value consistent with once-daily dosing; and (4) food does not appear to alter its bioavailability or pharmacokinetics.",Pharmacokinetics of dilevalol in normotensive and hypertensive volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729127/),h,8 to 12,216210,DB00598,Labetalol
,2454376,bioavailability,Carvedilol was absorbed rapidly after oral administration with a bioavailability of approximately 45% and obeyed linear pharmacokinetics over the dose range 25-50 mg.,A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454376/),%,45,224408,DB00598,Labetalol
,2454376,terminal elimination half-life,The terminal elimination half-life varied between 5 and 14 h.,A pharmacokinetic study of carvedilol (BM 14.190) in elderly subjects: preliminary report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2454376/),h,5 and 14,224409,DB00598,Labetalol
,8229771,total body clearance,"The fetal total body clearance of labetalol (50.45 +/- 1.37 ml m-1 kg-1), which was significantly higher than that previously determined in the ewe, was composed of transplacental and nonplacental CLs of 23.4 +/- 8.99 ml m-1 kg-1 and 27.05 +/- 10.36 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),[ml] / [kg·m],50.45,238585,DB00598,Labetalol
,8229771,CLs,"The fetal total body clearance of labetalol (50.45 +/- 1.37 ml m-1 kg-1), which was significantly higher than that previously determined in the ewe, was composed of transplacental and nonplacental CLs of 23.4 +/- 8.99 ml m-1 kg-1 and 27.05 +/- 10.36 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),[ml] / [kg·m],23.4,238586,DB00598,Labetalol
,8229771,CLs,"The fetal total body clearance of labetalol (50.45 +/- 1.37 ml m-1 kg-1), which was significantly higher than that previously determined in the ewe, was composed of transplacental and nonplacental CLs of 23.4 +/- 8.99 ml m-1 kg-1 and 27.05 +/- 10.36 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),[ml] / [kg·m],27.05,238587,DB00598,Labetalol
,8229771,area under the curve ratio,"The maternal to fetal plasma labetalol area under the curve ratio was 0.031 +/- 0.002 and the CLmp and CLmn were 7.27 +/- 2.11 ml m-1 kg-1 and 30.5 +/- 5.94 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),,0.031,238588,DB00598,Labetalol
,8229771,CLmp,"The maternal to fetal plasma labetalol area under the curve ratio was 0.031 +/- 0.002 and the CLmp and CLmn were 7.27 +/- 2.11 ml m-1 kg-1 and 30.5 +/- 5.94 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),[ml] / [kg·m],7.27,238589,DB00598,Labetalol
,8229771,CLmn,"The maternal to fetal plasma labetalol area under the curve ratio was 0.031 +/- 0.002 and the CLmp and CLmn were 7.27 +/- 2.11 ml m-1 kg-1 and 30.5 +/- 5.94 ml m-1 kg-1, respectively.","Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),[ml] / [kg·m],30.5,238590,DB00598,Labetalol
,8229771,net output,The calculated hind limb arteriovenous lactate flux showed a net output of lactic acid equal to 3.85 +/- 2.05 g from the hind limb over 24 h after labetalol administration.,"Transplacental and nonplacental clearances, metabolism and pharmacodynamics of labetalol in the fetal lamb after direct intravenous administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8229771/),g,3.85,238591,DB00598,Labetalol
,7924765,AUC,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[mg] / [l·min],148.9,242979,DB00598,Labetalol
,7924765,systemic clearance,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg·min],0.041,242980,DB00598,Labetalol
,7924765,volume of distribution,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg],1.543,242981,DB00598,Labetalol
,7924765,t1/2 beta,"For controls model-independent results were as follows: AUC = 148.9 +/- 9.0 mg/l x min, systemic clearance = 0.041 +/- 0.003 liters/min/kg, volume of distribution = 1.543 +/- 0.470 liters/kg, and t1/2 beta = 29.4 +/- 6.8 min.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,29.4,242982,DB00598,Labetalol
,7924765,distribution,"Cocaine followed two-compartment model kinetics with distribution and elimination half-lives of 0.3 +/- 0.1 and 58.0 +/- 18.0 min, respectively.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,0.3,242983,DB00598,Labetalol
,7924765,elimination half-lives,"Cocaine followed two-compartment model kinetics with distribution and elimination half-lives of 0.3 +/- 0.1 and 58.0 +/- 18.0 min, respectively.",Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,58.0,242984,DB00598,Labetalol
,7924765,systemic clearance,Labetalol significantly decreased systemic clearance to 0.029 +/- 0.004 liters/min/kg.,Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),[l] / [kg·min],0.029,242985,DB00598,Labetalol
,7924765,elimination half-life,BE kinetics revealed a elimination half-life of 230.0 +/- 83.2 min.,Effects of labetalol on cocaine pharmacokinetics in neonatal piglets. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7924765/),min,230.0,242986,DB00598,Labetalol
,3216030,total body clearance,"After intravenous administration, total body clearance and volume of distribution of unchanged dilevalol were determined to be 23.2 mL/min/kg and 24.6 L/kg, respectively.",Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),[ml] / [kg·min],23.2,243522,DB00598,Labetalol
,3216030,volume of distribution,"After intravenous administration, total body clearance and volume of distribution of unchanged dilevalol were determined to be 23.2 mL/min/kg and 24.6 L/kg, respectively.",Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),[l] / [kg],24.6,243523,DB00598,Labetalol
,3216030,maximum concentration,"After oral administration, a mean maximum concentration of 62 ng/mL was reached at an average peak time of 1.4 hours.",Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),[ng] / [ml],62,243524,DB00598,Labetalol
,3216030,peak time,"After oral administration, a mean maximum concentration of 62 ng/mL was reached at an average peak time of 1.4 hours.",Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),h,1.4,243525,DB00598,Labetalol
,3216030,half-life,Drug was eliminated with a half-life of 8.3 hours after oral administration and 12 hours after intravenous administration.,Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),h,8.3,243526,DB00598,Labetalol
,3216030,half-life,Drug was eliminated with a half-life of 8.3 hours after oral administration and 12 hours after intravenous administration.,Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),h,12,243527,DB00598,Labetalol
,3216030,absolute bioavailability,"Based on plasma levels and urinary excretion of total dilevalol, the drug was completely absorbed; however, due to first-pass metabolism, the absolute bioavailability of unchanged drug was 11 to 14%.",Pharmacokinetics and bioavailability of dilevalol in normotensive volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3216030/),%,11 to 14,243528,DB00598,Labetalol
,7093103,apparent volume of distribution,"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1).",Elimination kinetics of labetalol in severe renal failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093103/),[l] / [kg],3.3-7.9,247014,DB00598,Labetalol
,7093103,plasma clearance,"3 Labetalol has a relatively large apparent volume of distribution (3.3-7.9 l/kg, two-compartment open model) and a relatively high plasma clearance (0.3-1.6 1 h-1 kg-1).",Elimination kinetics of labetalol in severe renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7093103/),[1] / [h·kg],0.3-1.6,247015,DB00598,Labetalol
,2899094,Cmax,"In plasma, the mean Cmax for unchanged dilevalol, 485 ng/mL was reached at 0.8 hour (tmax) and the AUC(48 hours) was 1435 hr X ng/mL.",Secretion of dilevalol in breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),[ng] / [ml],485,250234,DB00598,Labetalol
,2899094,tmax,"In plasma, the mean Cmax for unchanged dilevalol, 485 ng/mL was reached at 0.8 hour (tmax) and the AUC(48 hours) was 1435 hr X ng/mL.",Secretion of dilevalol in breast milk. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),h,0.8,250235,DB00598,Labetalol
,2899094,AUC(48 hours),"In plasma, the mean Cmax for unchanged dilevalol, 485 ng/mL was reached at 0.8 hour (tmax) and the AUC(48 hours) was 1435 hr X ng/mL.",Secretion of dilevalol in breast milk. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),[h·ng] / [ml],1435,250236,DB00598,Labetalol
,2899094,half-lives,"Pharmacokinetic analysis of unchanged dilevalol in plasma showed that dilevalol was distributed and eliminated with half-lives of 0.9 and 8.2 hours, respectively.",Secretion of dilevalol in breast milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),h,0.9,250237,DB00598,Labetalol
,2899094,half-lives,"Pharmacokinetic analysis of unchanged dilevalol in plasma showed that dilevalol was distributed and eliminated with half-lives of 0.9 and 8.2 hours, respectively.",Secretion of dilevalol in breast milk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),h,8.2,250238,DB00598,Labetalol
,2899094,Cmax,"The milk Cmax, 149 ng/mL, occurred during the 0 to 2 hour collection interval; the AUC(42 hours) for unchanged dilevalol in milk was 663 hr X ng/mL.",Secretion of dilevalol in breast milk. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),[ng] / [ml],149,250239,DB00598,Labetalol
,2899094,AUC(42 hours),"The milk Cmax, 149 ng/mL, occurred during the 0 to 2 hour collection interval; the AUC(42 hours) for unchanged dilevalol in milk was 663 hr X ng/mL.",Secretion of dilevalol in breast milk. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),[h·ng] / [ml],663,250240,DB00598,Labetalol
,2899094,milk to plasma concentration ratio,The mean milk to plasma concentration ratio was 0.46.,Secretion of dilevalol in breast milk. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2899094/),,0.46,250241,DB00598,Labetalol
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"40,596",253780,DB00598,Labetalol
,6487478,AUC,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"22,057",253781,DB00598,Labetalol
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,30.3,253782,DB00598,Labetalol
,6487478,systemic bioavailability,"After glutethimide there was a significant reduction in the AUC after the oral dose of labetalol, from 40,596 +/- 11,534 (mean +/- s.e. mean) to 22,057 +/- 6,276 ng ml-1 min (2P less than 0.05), and systemic bioavailability was reduced from 30.3 +/- 2.8 to 17.0 +/- 3.5% (2P less than 0.001).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,17.0,253783,DB00598,Labetalol
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,520,253784,DB00598,Labetalol
,6487478,volume of distribution,"After cimetidine there was a significant reduction in the volume of distribution of labetalol, from 520 +/- 51 to 445 +/- 24 1 (2P less than 0.05).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),1,445,253785,DB00598,Labetalol
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"51,029",253786,DB00598,Labetalol
,6487478,AUC,"The AUC of labetalol after the oral dose increased by 66%, from 51,029 +/- 7,950 to 84,772 +/- 19,444 ng ml-1 min (2P = 0.06).",The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),[min·ng] / [ml],"84,772",253787,DB00598,Labetalol
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,25.1,253788,DB00598,Labetalol
,6487478,systemic bioavailability,The systemic bioavailability of labetalol increased from 25.1 +/- 2.4 to 39.0 +/- 7.6% (2P = 0.06).,The effects of enzyme induction and enzyme inhibition on labetalol pharmacokinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6487478/),%,39.0,253789,DB00598,Labetalol
,2349138,apparent oral clearance,No significant differences in the mean (SD) apparent oral clearance of the drug existed between groups after the first [4.8 (1.9) and 4.3 (1.2) L/hr/kg] and final [4.4 (2.2) and 3.4 (1.0) L/hr/kg] doses of labetalol.,Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349138/),[l] / [h·kg],4.8,256825,DB00598,Labetalol
,2349138,apparent oral clearance,No significant differences in the mean (SD) apparent oral clearance of the drug existed between groups after the first [4.8 (1.9) and 4.3 (1.2) L/hr/kg] and final [4.4 (2.2) and 3.4 (1.0) L/hr/kg] doses of labetalol.,Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349138/),[l] / [h·kg],4.3,256826,DB00598,Labetalol
,2349138,apparent oral clearance,No significant differences in the mean (SD) apparent oral clearance of the drug existed between groups after the first [4.8 (1.9) and 4.3 (1.2) L/hr/kg] and final [4.4 (2.2) and 3.4 (1.0) L/hr/kg] doses of labetalol.,Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349138/),[l] / [h·kg],4.4,256827,DB00598,Labetalol
,2349138,apparent oral clearance,No significant differences in the mean (SD) apparent oral clearance of the drug existed between groups after the first [4.8 (1.9) and 4.3 (1.2) L/hr/kg] and final [4.4 (2.2) and 3.4 (1.0) L/hr/kg] doses of labetalol.,Pharmacokinetics and pharmacodynamics of labetalol in elderly and young hypertensive patients following single and multiple doses. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2349138/),[l] / [h·kg],3.4,256828,DB00598,Labetalol
,7104169,systemic bioavailability,2 Food caused a 38% increase in the mean systemic bioavailability of labetalol: from 0.26 +/- 0.03 (mean +/- s.e. mean) to 0.36 +/- 0.05 (P less than 0.05).,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,0.26,260940,DB00598,Labetalol
,7104169,systemic bioavailability,2 Food caused a 38% increase in the mean systemic bioavailability of labetalol: from 0.26 +/- 0.03 (mean +/- s.e. mean) to 0.36 +/- 0.05 (P less than 0.05).,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,0.36,260941,DB00598,Labetalol
,7104169,volume of distribution,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),,567,260942,DB00598,Labetalol
,7104169,volume of distribution,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],685,260943,DB00598,Labetalol
,7104169,plasma clearance,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],1923,260944,DB00598,Labetalol
,7104169,plasma clearance,3 Food caused 20% increases in the volume of distribution of labetalol: (from 567 +/- 63 to 685 +/- 76) and in plasma clearance (from 1923 +/- 417 to 2344 +/- 566 ml/min.,The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7104169/),[ml] / [min],2344,260945,DB00598,Labetalol
,2693499,half-life,"It has a half-life of 15-18 hours, and is demonstrated to be effective as an antihypertensive agent for 24-30 hours.",Dilevalol: a selective beta-2 adrenergic agonist vasodilator with beta adrenergic blocking activity. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2693499/),h,15-18,265055,DB00598,Labetalol
